| Database ID | Agent | Target | Cancer Type | Detail |
| DB00181 | dabrafenib | BRaf protooncogene serine/threonineprotein kinase | melanoma | view |
| DB00182 | dabrafenib | BRaf protooncogene serine/threonineprotein kinase | melanoma | view |
| DB00183 | RAF265 | mRNA of RAF protooncogene serine/threonineprotein kinase | melanoma | view |
| DB00184 | dabrafenib | BRaf protooncogene serine/threonineprotein kinase | melanoma | view |
| DB00185 | trametinib | MEK2
Dual specificity mitogenactivated protein kinase kinase 1 | melanoma | view |
| DB00186 | dabrafenib | BRaf protooncogene serine/threonineprotein kinase | melanoma | view |
| DB00187 | dabrafenib | BRaf protooncogene serine/threonineprotein kinase | melanoma | view |
| DB00188 | cobimetinib | MEK | melanoma | view |
| DB00189 | dabrafenib and trametinib | BRAF¡¢MEK | melanoma | view |
| DB00190 | encorafenib (ENCO) and binimetinib (BINI) | BRAF and MEK | melanoma | view |
| DB00191 | BKM120 (PI3K inhibitor), BGJ398 (FGFR inhibitor), INC280 (cMet inhibitor) or ribociclib (LEE011; CDK4/6 inhibitor). | BKM120(PI3K delta, gamma, beta, alpha), BGJ398(Basic fibroblast growth factor receptor 1), LEE011(Cell division protein kinase 6
Cell division protein kinase 4) | melanoma | view |
| DB00192 | vemurafenib(BRAF inhibitor)+BKM120(PI3K inhibitor) | BRAF and PI3K | melanoma | view |
| DB00193 | binimetinib | MEK1/2 | melanoma | view |
| DB00194 | selumetinib | Dual specificity mitogenactivated protein kinase kinase | melanoma | view |
| DB00195 | imatinib mesylate | Abl
Plateletderived growth factor receptor
Mast/stem cell growth factor receptor | melanoma | view |